This article provides a practical overview of dermatologic medication use in pregnancy.
Objective:
The therapeutics of the following common dermatoses are reviewed: acne, psoriasis, and bacterial, fungal, viral, and parasitic infections. Antipruritic, analgesic, and topical anesthetic use in pregnancy is reviewed as well.
Conclusions:
At the end, the reader is challenged with a series of applied clinical scenarios that highlight the presented material and provide information on additional important medications.
Get full access to this article
View all access options for this article.
References
1.
HaleEKKeltz PomeranzM. Dermatological agents during pregnancy and lactation. An update and clinical review. Int J Dermatol2002;41:197–203.
2.
KorenGPastuszakAItuS. Drugs in pregnancy. N Engl J Med1998;338:1128–37.
3.
Nazzaro-PorroM. Azelaic acid. J Am Acad Dermatol1987;17:1033–41.
4.
AutretEBerjotMJonville-BerraAP. Anophthalmia and agenesis of optic chiasma associated with adapalene gel in early pregnancy. Lancet1997;350:339.
5.
Allergan. Tazorac [product information]. 2004.
6.
RaychaudhuriSPNovareTGrossJ. Clinical course of psoriasis during pregnancy. Int J Dermatol2003;42:518–20.
7.
TausherAEFleischerABJrPhelpsKCFeldmanSR. Psoriasis and pregnancy. J Cutan Med Surg2002;6:561–70.
8.
LebwohlM. Topical application of calcipotriene and corticosteroids: Combination regimens. J Am Acad Dermatol1997;37 (3 pt 2):S55–8.
9.
GilstrapLCLittleBB. Drugs and pregnancy. 2nd ed.New YorkChapman and Hall, International Thomson Publishing, Thomson Science; 1998.
10.
AshtonREAndréPLoweNJ. Anthralin: Historical and current perspectives. J Am Acad Dermatol1983;9:173–92.
11.
JureckaWGebhartW. Drug prescribing during pregnancy. Semin Dermatol1989;8:30–9.
12.
SternRSLangeR. Outcome of pregnancies among women and partners of men with a history of exposure to PUVA for the treatment of psoriasis. Arch Dermatol1991;127:347–50.
13.
PhamCTKuoJY. Plasma levels of 8-methoxypsoralen after topical paint PUVA. J Am Acad Dermatol1993;28:460–6.
14.
FeldmanSRMellenBGHousmanTS. Efficacy of the 308-nm excimer laser for treatment of psoriasis: Results of a multicenter study. J Am Acad Dermatol2002;46:900–6.
15.
FeldmanS. Advances in psoriasis treatment. Dermatol Online J2000;6:4.
16.
KooYM. Current consensus and update on psoriasis therapy: A perspective from the United States. J Dermatol1999;26:723–33.
17.
CockburnIKruppPMonkaC. Present experience of Sandimmune® in pregnancy. Transplant Proc1989;21:3730–2.
18.
MahadevanUKaneSSandbornWJ. Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease. Aliment Pharmacol Ther2005;21:733–8.
19.
ChakravartyEFSanchez-YamamotoDBushTM. The use of disease modifying antirheumatic drugs in women with rheumatoid arthritis of childbearing age: A survey of practice patterns and pregnancy outcomes. J Rheumatol2003;30:241–6.
20.
ShaeferCAmoura-ElefantE. Pregnancy outcome after prenatal quinolone exposure. Evaluation of a case registry of the European Network of Teratology Information Service (ENTIS). Eur J Obstet Gynecol Reported Biol1996;69:83–9.
21.
CohlanSQ. Tetracycline staining of teeth. Teratology1977;15:127–30.
22.
StirratGM. Prescribing problems in the second half of pregnancy and during lactation. Obstet Gynecol Surv1976;1:311–7.
23.
Bar-OzBMorettiMEBishaiR. Pregnancy outcome after in utero exposure to itraconazole: A prospective cohort study. Am J Obstet Gynecol2000;183:617–20.
24.
SobelJD. Use of antifungal drugs in pregnancy: A focus on safety. Drug Saf2000;23:77–85.
25.
HollierLMWorkowskiK. Treatment of sexually transmitted infections in pregnancy. Clin Perinatal2005;32:629–56.
26.
SassevilleD. Dermatological therapy during pregnancy and lactation. In: HarahapMWallachRC, editors. Skin changes and diseases in pregnancy. New York Marcel Dekker; 1996. p. 249–319.
27.
Drugs for sexually transmitted infections. Med Lett Drugs Ther1999;41:85–90.
28.
ArenaSMarconiMFregaA. Pregnancy and condyloma. Evaluation about therapeutic effectiveness of laser CO2 on 115 pregnant women. Minerva Ginecol2001;53:389–96.
29.
Centers for Disease Control and Prevention. Sexually transmitted disease treatment guidelines 2002. MMWR Recomm Rep2002;51(RR-6):1–78.
30.
BriggsGGFreemanRKYaffeSJ, editors. Drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk. 5th ed.Baltimore: Williams and Wilkins; 1998.
31.
ShueyDLBuckalewARWilkeTS. Early events following maternal exposure to 5-fluorouracil lead to dysmorphology in cultured embryonic tissues. Teratology1994;50:379–86.
32.
American Academy of Pediatrics Committee on Drugs. The transfer of drugs and other chemicals into human milk. Pediatrics1994;93:137–50.
33.
PacqueMMunorBPoetschkeG. Pregnancy outcomes after inadvertent ivermectin treatment during community based distribution. Lancet1990;336:1486–9.
34.
Diav-CitrinO. Pregnancy outcome after gestational exposure to mebendazole: A prospective controlled cohort study. Am J Obstet Gynecol2003;188:5–6.
35.
SchatzMPetittiD. Antihistamines and pregnancy. Ann Allergy Asthma Immunol1997;78:157–9.
36.
ReedBR. Dermatologic drugs during pregnancy and lactation. In: WolvertonSE, editor. Comprehensive dermatologic drug therapy. Philadelphia: W.B. Saunders; 2001. p. 817–47.
37.
MazzottaPLoebsteinRKorenG. Treating allergic rhinitis in pregnancy, safety considerations. Drug Saf1999;20:361–75.
38.
KozerE. Aspirin consumption during the first trimester of pregnancy and congenital anomalies, a meta-analysis. Am J Obstet Gynecol2002;184:1623–30.
39.
LevyMSpinoM. Neonatal withdrawal syndrome: Associated drugs and pharmacologic management. Pharmacotherapy1993;13:202–11.
40.
HeinonenOPSloneDShapiroS. Birth defects and drugs in pregnancy. Littleon (MA): Publishing Sciences Group; 1977. p. 484.
41.
PirsonYVan LierdaMGhysenJ. Retardation of fetal growth in patients receiving immunosuppressive therapy [letter]. N Engl J Med1985;313:328.
42.
JanssenNMGentaMS. The effect of immunosuppressive and anti-inflammatory medications on fertility, pregnancy, and lactation. Arch Intern Med2000;160:610–9.
43.
CzeizelAERockenbauerM. Population based case-control study of teratogenic potential of corticosteroids. Teratology1997;156:335–40.
44.
RabinovitchOZemerDKukiaE. Colchicine treatment in conception and pregnancy: Two hundred thirty one pregnancies in patients with familial Mediterranean fever. Am J Reprod Immunol1992;28:245–6.
45.
BordenMBParkeAL. Antimalarial drugs in systemic lupus erythematosus: Use in pregnancy. Drug Saf2001;24:1055–63.
46.
CampRDR. Psoriasis. In: ChampionRH, editor. Rook/Wilkinson/Ebling textbook of dermatology. Oxford (UK): Blackwell Science; 1998. p. 1642.
47.
ArmentiVTRadomskiJSMoritzMJ. Report from the National Transplantation Pregnancy Registry (NTPR): Outcomes of pregnancy after transplantation. Clin Transpl2002:121–30.
48.
BothamleyG. Drug treatment for tuberculosis during pregnancy: Safety considerations. Drug Saf2001;24:553–65.
49.
MastroiacovoPMazzoneTBottoLD. Prospective assessment of pregnancy outcome after first-trimester exposure to fluconazole. Am J Obstet Gynecol1996;175:1645–50.
50.
MorrisLFHarrodMJMenterMASilvermanAK. Methotrexate and reproduction in men: Case report and recommendations. J Am Acad Dermatol1993;29:913–6.
51.
SoterNAFleisherABWebsterGF. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: Part II, safety. J Am Acad Dermatol2001;44:539–46.
52.
AllenASiegfriedESilvermanR. Significant absorption of topical tacrolimus in three patients with Netherton syndrome. Arch Dermatol2001;137:747–50.
